L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain

被引:82
作者
Bezard, E
Gross, CE
Qin, L
Gurevich, VV
Benovic, JL
Gurevich, EV
机构
[1] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA
[2] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[3] China Agr Univ, Lab Anim Res Ctr, Beijing, Peoples R China
[4] Univ Bordeaux 2, CNRS UMR 5543, F-33076 Bordeaux, France
关键词
arrestin; G protein-coupled receptor kinase; dyskinesia; Parkinson disease;
D O I
10.1016/j.nbd.2004.10.005
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Dysregulation of dopamine receptors (DARs) is believed to contribute to Parkinson disease (PD) pathology. G protein-coupled receptors (GPCR) undergo desensitization via activation-dependent phosphorylation by G protein-coupled receptor kinases (GRKs) followed by arrestin binding. Using quantitative Western blotting, we detected profound differences in the expression of arrestin2 and GRKs among four experimental groups of nonhuman primates: (1) normal, (2) parkinsonian, (3) parkinsonian treated with levodopa without or (4) with dyskinesia. Arrestin2 and GRK6 expression was significantly elevated in the MPTP-lesioned group in most brain regions; GRK2 was increased in caudal caudate and internal globus pallidus. Neither levodopa-treated group differed significantly from control. The only dyskinesia-specific change was an elevation of GRK3 in the ventral striatum of the dyskinetic group. Changes in arrestin and GRK expression in the MPTP group were accompanied by enhanced ERK activation and elevated total ERK expression, which were also reversed by L-DOPA. The data suggest the involvement of arrestins and GRKs in Parkinson disease pathology and the effects of levodopa treatment. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:323 / 335
页数:13
相关论文
共 74 条
[61]  
PREMONT RT, 1994, J BIOL CHEM, V269, P6832
[62]   Expression of D3 receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration:: Effect of levodopa treatment [J].
Quik, M ;
Police, S ;
He, L ;
Di Monte, DA ;
Langston, JW .
NEUROSCIENCE, 2000, 98 (02) :263-273
[63]  
RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249
[64]   Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice [J].
Rockman, HA ;
Choi, DJ ;
Rahman, NU ;
Akhter, SA ;
Lefkowitz, RJ ;
Koch, WJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (18) :9954-9959
[65]   Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease [J].
Ryoo, HL ;
Pierrotti, D ;
Joyce, JN .
MOVEMENT DISORDERS, 1998, 13 (05) :788-797
[66]  
Sallese M, 1997, J BIOL CHEM, V272, P10188
[67]  
STERNEMARR R, 1993, J BIOL CHEM, V268, P15640
[68]   Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias [J].
Stocchi, F ;
Nordera, G ;
Marsden, CD .
CLINICAL NEUROPHARMACOLOGY, 1997, 20 (02) :95-115
[69]  
Todd RD, 1996, J NEUROSCI, V16, P7776
[70]   The stability of the G protein-coupled receptor-β-arrestin interaction determines the mechanism and functional consequence of ERK activation [J].
Tohgo, A ;
Choy, EW ;
Gesty-Palmer, D ;
Pierce, KL ;
Laporte, S ;
Oakley, RH ;
Caron, MG ;
Lefkowitz, RJ ;
Luttrell, LM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (08) :6258-6267